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Old yellow enzyme (OYE) is an NADPH oxidoreductase which contains ﬂavin
mononucleotide as prosthetic group. The X-ray structures of OYE from
Trypanosoma cruzi (TcOYE) which produces prostaglandin (PG) F2 from
PGH2 have been determined in the presence or absence of menadione. The
binding motif of menadione, known as one of the inhibitors for TcOYE, should
accelerate the structure-based development of novel anti-chagasic drugs that
inhibit PGF2 production speciﬁcally.
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1. Introduction
Prostaglandin (PG) F2 synthase (PGFS) is the enzyme which
produces PGF2 from the PGH2, and was ﬁrst isolated from
mammals (Watanabe et al., 1985). Mammalian PGFSs belong
to aldo-ketoreductases (Bohren et al., 1989; Bruce et al.,
1994), which are NAD(P)(H)-dependant oxidoreductase. In
mammals, PGF2 is a potent mediator of various physiological
processes (Narumiya et al., 1999; Glew, 1992; Samuelsson,
1979) including vasculartone, constriction of uterine muscle
(Bygdeman et al., 1970) and pulmonary arteries (Oliw et al.,
1983; Mathe et al., 1977), and induction of luteolysis during the
estrous cycle and prior to parturition (Horton & Poyser, 1976;
McCracken et al., 1972). During pathological processes in
mammals, PGF2 overproduction causes ovarian dysfunction
and miscarriage (Dubois et al., 1998; Mutayoba et al., 1989;
Davies et al., 1984).
PGF2 is produced not only in mammals but also in parasitic
protozoa which causes serious infections, such as Plasmodium
falciparum (Kubata et al., 1998), Trypanosoma brucei (Kubata
et al., 2000; Okano et al., 2002; Kilunga et al., 2005) and
Leishmania major (Kabututu et al., 2002, 2003). Owing to their
identiﬁcation, pathological relationships of parasitic PGFSs
with human disease have begun to emerge. For example, it is
thought that PGFS from Trypanosoma brucei (TbPGFS) plays
a role in pathogenesis trypanosomiasis because African
trypanosomiasis is characterized by miscarriage owing to
PGF2 overproduction correlated with parasitemia peaks
(Mutayoba et al., 1989). Therefore, the study of parasitic PGFS
is quite signiﬁcant because it can lead to investigation of the
pathological roles and development of the inhibitor of PGFS
for remedies.
Chagas disease, caused by Trypanosoma cruzi, affects more
than 20 million people and poses a major public health and
economic problem in South America (World Health Organi-
zation, 1990). This situation has been worsened by the lack of
effective vaccines and undesirable side effects of anti-chagasic
drugs, such as nifurtimox and benznidazole (Aldunate &
Morello, 1993; Henderson et al., 1988; Docampo & Moreno,
1986; Docampo, 1990), in addition to the emergence of para-
site resistance to these drugs. Therefore, the development of a
new chemotherapeutic treatment is an urgent need.
PGFS from T. cruzi was identiﬁed by Kubata et al. and it
was found that this enzyme belonged to old yellow enzyme
(OYE) (Kubata et al., 2002). OYE was originally isolated from
brewers’ bottom yeast in the 1930s, and the ﬁrst protein
requiring a vitamin B2-derived molecule, ﬂavin mononucleo-
tide (FMN), of its catalysis (Warburg, 1933; Schopfer &
Massey, 1991). The previously detected OYE families from
bacteria (Warburg, 1933; Matthews & Massey, 1969), yeast
(Schaller & Weiler, 1997) and plants (French et al., 1996;
Blehert et al., 1999) are able to reduce a variety of compounds,
such as unsaturated aldehydes and ketones (French & Bruce,
1994; Vaz et al., 1995), nitro-esters (French et al., 1996; Snape et
al., 1997; Blehert et al., 1999; Meah & Massey, 2000) and nitro-
aromatic substrates (French et al., 1998; Pak et al., 2000;
Williams et al., 2004).
OYE from T. cruzi (TcOYE) catalyzes prostaglandin F2
synthesis (Fig. 1) as well as the reduction of many kinds of
trypanocidal drugs, such as naphtoquinone and nitrohetero-cyclic compounds (Kubata et al., 2002). By electron spin
resonance it was found that these compounds can undergo
either one- or two-electron reduction. Naphtoquinone, such as
menadione (Km = 0.82 mM)o r-lapachone (Km = 0.17 mM), is
reduced by one-electron reduction, generating semiquinone
radicals which cause the cell death in susceptible parasites,
while nitroheterocyclic compounds, such as 4-nitroquinoline-
N-oxide (Km =9 . 5mM) or nifurtimox (Km = 19.0 mM), are
reduced by two-electron reduction (Kubata et al., 2002).
Therefore, three-dimensional information of the structure in
complex with the quinine compounds is valuable for the
design of novel anti-chagasic drugs by which semiquinone
radicals are more efﬁciently generated in T. cruzi.
Here we report the ﬁrst X-ray structures of TcOYE which
produces PGF2 from PGH2 in the presence or absence of
menadione. The structural analysis of TcOYE/FMN/mena-
dione ternary complex has provided the binding motif of
menadione at the active site. These structures are useful for
further drug design for Chagas disease.
2. Materials and methods
2.1. Protein expression and crystallization
Chemicals were obtained from Sigma-Ardrich at the
highest available purity. TcOYE was overexpressed in E. coli
and puriﬁed, and TcOYE/FMN binary complex was crystal-
lized according to previously reported methods (Kubata et al.,
2002; Sugiyama et al., 2007). These crystals were ﬂash-cooled
in liquid nitrogen with cryo-protectant solution containing 3%
(v/v) 2-methyl-2,4-pentanediol. The X-ray diffraction data
were obtained up to 1.70 A ˚ resolution at SPring-8 beamline
BL41XU. The diffraction data were processed and scaled
using the program HKL2000 (Otwinowski & Minor, 1997).
2.2. Structure determination and refinement
The structure of TcOYE was determined by molecular
replacement with the program AMoRe (Navaza, 2001) using
the structure of morphinone reductase from Pseudomonas
putida (Protein Data Bank code 1gwj) (Barna et al., 2002) as a
search model. Crystallographic reﬁnement was carried out
with the program CNS (Bru ¨nger et al., 1998). The reﬁnement
procedure included simulated annealing, positional reﬁne-
ment, restrained temperature factor reﬁnement, and
maximum-likelihood algorithms as provided by the CNS
program. Electron density maps based on the coefﬁcients of
2Fo  Fc and Fo  Fc were used to build the atomic models
in Coot (Emsley & Cowtan, 2004). Water molecules were
inserted manually and then checked by inspecting the Fo  Fc
map. FMN (cofactor) and menadione (ligand) were reﬁned
using atomic parameters extracted from the HIC-UP server
(Kleywegt & Jones, 1998), and could be inserted into the
clearly deﬁned electron density model after some cycles of
reﬁnement.
2.3. Preparation of TcOYE complexed with menadione
In order to prepare the complex crystals with menadione,
the crystals of the TcOYE/FMN complex were soaked in a
menadione solution for 16 h and then the crystals were ﬂash
frozen in liquid nitrogen. The X-ray diffraction data were
obtained up to 2.5 A ˚ resolution by using Ultrax18 (Rigaku).
Data collection, structure determination and reﬁnement were
carried out by the same methods as described above.
3. Results and discussion
3.1. Overall structure of TcOYE
The structure of TcOYE/FMN binary complex was deter-
mined by molecular replacement methods using that of
morphinone reductase (Barna et al., 2002) as the searching
model and reﬁned at 1.7 A ˚ resolution with ﬁnal Rcryst/Rfree
values of 18.5%/23.2%. Our crystallographic properties and
reﬁnement statistics of the structure are presented in Table 1.
TcOYE, like other members of the OYE family, folds into
an (/)8 barrel in which the cylindrical core composed of
eight parallel -strands (1–8) is surrounded by eight -
helices (1–8). In addition, an N-terminal -hairpin (S1 and
S2) closes the bottom of the barrel and two extra helices (H1
and H2) lie in the loops connecting 4t o4 and 8t o8,
respectively (Fig. 2). The loop regions from 105 to 165 (Loop
1) and 351 to 379 (Loop 2) exhibit the relatively higher B-
factors of 21.3 and 18.8 A ˚ 2, respectively, while the overall B-
factor of TcOYE without those two loop ranges was calculated
to be 13.1 A ˚ 2. This difference in the B-factor shows the ﬂex-
ibility of these two loops.
3.2. FMN binding site
FMN is tightly bound at the C-terminal ends of the eight -
strands in the barrel and exhibits quite low B-factors (Fig. 3).
Most amino acid residues which bind to the riboﬂavin moiety
of FMN are highly conserved among the different known
OYE structures, except Ala61. Ala61 in TcOYE was
conserved as alanine or glycine among the known OYE
structures; however, the amide nitrogen atom of the corre-
sponding amino acid interacts with O4 of FMN. On the other
hand, three residues bound to the phosphate O atoms in FMN
are not conserved: the side chain of Asn313 and the main
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Figure 1
Reduction of PGH2 to PGF2 by TcOYE. FMN (cofactor of TcOYE) is
reduced to FMNH2 by intravital nicotinamide adenine dinucleotide
phosphate (NADPH), and the product PGF2 is subsequently generated
by FMNH2.chains of Leu314 and Lys338 interact with the phosphate O
atoms through water molecules.
3.3. The binding motif of menadione
In order to develop more effective inhibitors we have
solved the structure of TcOYE/FMN/menadione ternary
complex at 2.5 A ˚ resolution (Table 1). The whole structure of
TcOYE does not change even upon binding of menadione.
The binding motif of menadione is deﬁned in the difference
electron density maps even at low occupancy (Fig. 4). The
cause of its low afﬁnity (Km = 0.82 mM) is assumed to be
because the ligand is stabilized by only a – interaction with
the isoalloxazien ring of FMN. To increase the afﬁnity of
menadione, interactions with His195, Asn198 or Tyr 364
should be designed in the future.
4. Conclusion
We have solved the structures of TcOYE in the presence or
absence of menadione. The binding motif of the inhibitor at
the active site of TcOYE has been elucidated from TcOYE/
FMN/menadione ternary complex. Future work is in progress
to obtain the structure in complex with other inhibitors to
elucidate the reaction mechanism of TcOYE in detail, which
can be expected to lead to the development of heroic anti-
chagasic drugs.
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Figure 2
The overall structure of TcOYE. The -helices (cyan) and -sheets
(orange) are separated among them by loops (light yellow). Loop 1 and
Loop 2 are shown in magenta. FMN is shown as a ball-and-stick model.
The image was created by using MOLSCRIPT (Kraulis, 1991) and
RASTER3D (Merritt & Murphy, 1994).
Figure 3
FMN binding model with 2Fo  Fc omit map. The FMN electron density
is calculated at 1.7 A ˚ and contoured at 2.5 . O, N and P atoms are shown
in red, blue and magenta, respectively. Labelled residues indicate those
involved in FMN binding. The ﬁgure was drawn using the programs
MOLSCRIPT and RASTER3D.
Figure 4
The binding site of menadione. Menadione (green) is positioned above
the isoalloxazine ring of FMN. The menadione electron density is
calculated at 2.5 A ˚ and contoured at 1.2 . The ﬁgure was drawn using the
program PyMOL (DeLano, 2005).
Table 1
Data collection and reﬁnement statistics for TcOYE/FMN and TcOYE/
FMN/menadione.
Values in parentheses are for the highest resolution shell.
TcOYE/FMN TcOYE/FMN/menadione
Beamline SPring-8 BL41XU Ultrax18
Space group P21 P21
Cell constants (A ˚ , ) a = 56.29, b = 78.79,
c = 78.80,  = 93.37
a = 47.58, b = 53.66,
c = 120.00,  = 90.004
Resolution range (A ˚ ) 50.0–1.70 (1.76–1.70) 50.0–2.5 (2.54–2.50)
No. of molecules per
asymmetric unit
22
VM (A ˚ 3 Da
1) 2.1 1.8
Vsolv (%) 41 35
No. of measured
reﬂections
424814 70984
No. of unique
reﬂections
75469 20908
I/(I) 6.3 6.8
Rmerge (%)† 7.0 (27.4) 3.5 (6.2)
Completeness (%) 100.0 (100.0) 98.1 (95.0)
Rcryst (%)‡ 18.5 33.2
Rfree (%)§ 23.2 40.9
R.m.s. deviations
Bonds (A ˚ ) 0.005 0.01
Angles () 1.4 1.7
† Rmerge = |I(k)  I|/I(k), where I(k) is the value of the kth measurement of the
intensity of a reﬂection, I is the mean value of the intensity of that reﬂection, and
the summation is over all measurements. ‡ Rcryst = ||Fo|  |Fc||/|Fo|, calculated
from 90% of the data, which were used during the course of the reﬁnement. § Rfree =
||Fo|  |Fc||/|Fo|, calculated from 10% of the data, which were obtained during the
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